TY - JOUR
T1 - The efficacy, safety, and predictors of outcomes of transarterial radioembolization for hepatocellular carcinoma
T2 - a retrospective study
AU - Abdallah, Mohamed A.
AU - Wongjarupong, Nicha
AU - Hassan, Mohamed A.
AU - Taha, Wesam
AU - Abdalla, Abubaker
AU - Bampoh, Sally
AU - Onyirioha, Kristeen
AU - Nelson, Morgan
AU - Glubranson, Lyn A.
AU - Wiseman, Gregory A.
AU - Fleming, Chad J.
AU - Andrews, James C.
AU - Mahipal, Amit
AU - Roberts, Lewis R.
N1 - Publisher Copyright:
© 2020 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2020/7/2
Y1 - 2020/7/2
N2 - Objectives: Yttrium-90 transarterial radioembolization (TARE) is a safe, effective modality of locoregional therapy for intermediate and advanced-stage hepatocellular carcinoma (HCC). We aim to identify novel predictors of important outcomes of TARE therapy. Methods: A single-center retrospective study of 166 patients treated with TARE for HCC at Mayo Clinic Rochester between 2005-2015 and followed until December 2017. Multivariate logistic and stepwise regression analysis models were used to identify variables associated with overall survival (OS) and progression-free survival (PFS). Results: The median OS and the median PFS were12.9 (95% CI: 11.0–17.3), and 8 months (95% CI: 6–11), respectively. Macrovascular invasion (HR: 1.9 [1.3–2.8]), Child-Pugh score (CPS) B or C vs. A (HR: 1.8 [1.2–2.7]), Eastern Cooperative Oncology Group Performance status (ECOG-PS) 2 or 1 vs. 0 (HR: 1.6 [1.1–2.4]) and activity (A) of administered radiation dose (HR: 1.005[1.00–1.010), independently correlated with poorer OS. Infiltrative HCC (HR: 2.4 [1.3–4.5), macrovascular invasion (HR: 1.6 [1.1–2.7]), and high activity of administered radiation dose (HR: 1.005 [1.00–1.010) were associated with worse PFS. Conclusion: In HCC patients treated with TARE; macrovascular invasion, the activity of radiation dose, CPS, ECOG-PS, and infiltrative HCC predict OS and PFS.
AB - Objectives: Yttrium-90 transarterial radioembolization (TARE) is a safe, effective modality of locoregional therapy for intermediate and advanced-stage hepatocellular carcinoma (HCC). We aim to identify novel predictors of important outcomes of TARE therapy. Methods: A single-center retrospective study of 166 patients treated with TARE for HCC at Mayo Clinic Rochester between 2005-2015 and followed until December 2017. Multivariate logistic and stepwise regression analysis models were used to identify variables associated with overall survival (OS) and progression-free survival (PFS). Results: The median OS and the median PFS were12.9 (95% CI: 11.0–17.3), and 8 months (95% CI: 6–11), respectively. Macrovascular invasion (HR: 1.9 [1.3–2.8]), Child-Pugh score (CPS) B or C vs. A (HR: 1.8 [1.2–2.7]), Eastern Cooperative Oncology Group Performance status (ECOG-PS) 2 or 1 vs. 0 (HR: 1.6 [1.1–2.4]) and activity (A) of administered radiation dose (HR: 1.005[1.00–1.010), independently correlated with poorer OS. Infiltrative HCC (HR: 2.4 [1.3–4.5), macrovascular invasion (HR: 1.6 [1.1–2.7]), and high activity of administered radiation dose (HR: 1.005 [1.00–1.010) were associated with worse PFS. Conclusion: In HCC patients treated with TARE; macrovascular invasion, the activity of radiation dose, CPS, ECOG-PS, and infiltrative HCC predict OS and PFS.
KW - Neutrophil to lymphocyte ratio
KW - child-pugh score
KW - hepatocellular carcinoma
KW - macrovascular invasion
KW - monocyte to lymphocyte ratio
KW - platelet to lymphocyte ratio
KW - transarterial radioembolization
UR - http://www.scopus.com/inward/record.url?scp=85087364746&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087364746&partnerID=8YFLogxK
U2 - 10.1080/17474124.2020.1777856
DO - 10.1080/17474124.2020.1777856
M3 - Article
C2 - 32490691
AN - SCOPUS:85087364746
SN - 1747-4124
VL - 14
SP - 619
EP - 629
JO - Expert Review of Gastroenterology and Hepatology
JF - Expert Review of Gastroenterology and Hepatology
IS - 7
ER -